Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) released its quarterly earnings data on Thursday. Here are the key takeaways from Neurocrine Biosciences’ conference call:Get Neurocrine Biosciences alerts:Strong commercial performance: Q2 revenue exceeded $950 million, up nearly 40% year over year, with non-GAAP EPS of $2.85. Neurocrine Biosciences Price PerformanceNeurocrine Biosciences stock traded up $4.71 during midday trading on Thursday, hitting $185.50. Neurocrine Biosciences Company Profile(Get Free Report)Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Featured StoriesReceive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.